In June 29, 2016 the FDA has approved the first Dental Nasal Spray (KOVANASE).And in 21October, 2016 St. Renatus, LLC announced that Kovanaze™ (tetracaine HCl and oxymetazoline HCl) Nasal Spray, the first FDA-approved, needle-free, regional dental anesthesia for the maxillary arch, is available for pre-order.
Kovanaze is intended for use in dentistry as a topical anesthetic, delivered in the nasal cavity to achieve pulpal (tooth nerve) anesthesia for the restorative treatment of teeth. Like traditional dental injections, this product delivers a local dental anesthetic but without the needle.
Kovanaze is indicated for regional anesthesia when performing a restorative procedure on Teeth 4-13 (#15 – #25) and A-J in adults and children who weigh 40 kg or more. KOVANAZE contains tetracaine HCl, an ester local anesthetic, and oxymetazoline HCl, a vasoconstrictor.
Join the discussion One Comment
Are dental hygienists allowed to use Kovanaze on patients with or without dentist supervision?